Outlook Therapeutics is trading 11.81% down at $0.97 after no clear company-specific announcement was identified for August 12, 2026.
- The decline is occurring despite gains in the S&P 500 and Nasdaq Composite, so broader-market sentiment does not clearly explain the move.
- Investors may be focused on fiscal third-quarter results scheduled for August 14, 2026; no results have been released yet.